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Multiple sclerosis (MS) is a chronic inﬂammatory disease characterized by central
nervous system (CNS) demyelination and axonal degeneration. Although the cause of
MS is still unknown, it is widely accepted that novel drug targets need to focus on both
decreasing inﬂammation and promoting CNS repair. In MS and experimental autoimmune
encephalomyelitis, non-coding small microRNAs (miRNAs) are dysregulated in the immune
system and CNS. Since individual miRNAs are able to down-regulate multiple targeted
mRNA transcripts, even minor changes in miRNA expression may lead to signiﬁcant
alterations in gene expression. Herein, we review miRNA signatures reported in CNS
tissue and immune cells of MS patients and consider how altered miRNA expression may
inﬂuence MS pathology.
Keywords: miRNA, multiple sclerosis, myelin, MS lesions, immune system
INTRODUCTION
Multiple sclerosis (MS) is a chronic demyelinating neurode-
generative disease of the central nervous system (CNS) with
an unknown etiology. Several lines of evidence suggest that
developing this autoimmune disease depends on both environ-
mental and genetic factors, which is supported by genome-wide
association studies. Although the exact pathogenesis of MS
remains to be fully elucidated, the pathology of MS suggests
an autoimmune etiology and includes inﬁltration of T cells, B
cells, and macrophages in active MS brain lesions. The immune
attack in the CNS is mediated by autoreactive T cells that
enter through a disrupted blood–brain barrier (BBB) and attack
oligodendrocytes and myelin. While CD4+ T cells are consid-
ered essential in the initial stages of CNS inﬂammation, both
adaptive and innate (microglia/macrophages) immune mecha-
nisms contribute to inﬂammation and tissue injury (Prat and
Antel, 2005; Becher et al., 2006). In the periphery and CNS,
altered cytokine proﬁles (e.g., TNF-α, IFN-γ, IL-17, IL-6, and
IL-18) contribute to the pathological features of MS, such as
demyelination, loss of oligodendrocytes, and axonal degenera-
tion (Lucchinetti et al., 2000; Bjartmar et al., 2003; Imitola et al.,
2005). The balance between Th1 (pro-inﬂammatory) and Th2
(anti-inﬂammatory) mechanisms contributes to injury, but also
repair. Several cytokines (including Th1 and Th2) are implicated
in the survival and differentiation of neurons, oligodendrocytes,
and oligodendrocyte progenitor cells (OPCs). Given the contribu-
tion of cytokines and chemokines to CNS injury and repair, tight
transcriptional and translational regulation of these molecules is
required. In recent years, microRNAs (miRNAs) have emerged as
important regulators of cytokine and growth factor expression,
and have been suggested as disease biomarkers and targets of
therapy.
MicroRNAs are evolutionarily conserved, short non-coding
RNAs that regulate gene expression in health and disease, dur-
ing development, immune system activation, neurogenesis, and
myelin formation in the CNS. Several studies have implicated the
disruption of miRNA function in human diseases. In MS, miRNA
proﬁles are altered within CNS lesions and in the immune sys-
tem, and affect gene expression in many cell types involved in
the disease. A global consideration of miRNA dysregulation and
the resulting alterations in gene expression may provide valu-
able insights into the pathophysiology of MS and reveal new
alternatives for early diagnosis and treatment.
miRNA DYSREGULATION IN THE IMMUNE SYSTEM
In the human immune system, miRNAs play an important role
in modulating innate immune responses against bacteria, viruses,
and other pathogens. These inﬂammatory responses of immune
cells against invading pathogens must be efﬁciently and tightly
regulated. miRNAs also inﬂuence the development and regulation
of the adaptive immune system. Biological activities of T and B
cells are inﬂuenced by speciﬁc miRNAs. More speciﬁcally, miR-
NAs regulate B and T cell development and differentiation, in
addition to pro-inﬂammatory responses mediated by Treg cells.
Given the complex pathobiology of MS and the involvement of
both innate and adaptive immunity, examining miRNA proﬁles in
speciﬁc immune cell subsetsmay reveal potential novel biomarkers
and further elucidate underlying mechanisms.
MicroRNAs have been identiﬁed that are differentially
expressed between MS disease subtypes and healthy individuals.
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Several of these studies have used high-throughput miRNA proﬁl-
ing to identify key miRNAs unique to different aspects of disease.
RNA sources have included whole blood, serum, peripheral
blood mononuclear cells (PBMCs), and lymphocytes. Signiﬁ-
cantly decreased levels of miR-17 and miR-20a have been detected
in whole blood in all MS subtypes compared with healthy con-
trols. Notably, miR-17 and miR-20a block genes involved in T
cell activation (Cox et al., 2010). Also in whole blood, 165 miR-
NAs were reported to be signiﬁcantly up- or down-regulated;
with miR-145 identiﬁed as a highly sensitive, speciﬁc, and
accurate miRNA (Keller et al., 2009). Additional studies have
isolated PBMCs from MS patients during both relapses and
remissions, and have identiﬁed differential expression of miR-
18b, miR-493, and miR-599, which have been implicated in
interleukin and wnt signaling (Otaegui et al., 2009). miR-21,
miR-146a, and miR-146b have also been reported to be signiﬁ-
cantly increased in whole PBMCs from relapsing-remitting mul-
tiple sclerosis (RRMS) patients compared with controls (Fenoglio
et al., 2011).
The importance of correlating disease-relevant functions with
altered miRNA levels has prompted others to proﬁle individual
miRNAs within immune cell subsets (Figure 1). In CD4+ T cells,
higher levels of miR-17-5p was found in RRMS patients, lead-
ing to down-regulation of targeted genes (Lindberg et al., 2010).
In contrast, miR-15a and miR-16-1 are down-regulated in CD4+
T cells from RRMS patients (Lorenzi et al., 2012). These authors
suggest that elevated levels of bcl-2 in CD4+ T cells from MS
patients result from decreased levels of miR-15a and miR-16-1,
which target this potent anti-apoptotic gene (Lorenzi et al., 2012).
miR-128 and miR-27b are signiﬁcantly elevated in naïve T cells
from MS patients compared with healthy controls, while miR-340
was increased inmemory T cells (Guerau-de-Arellano et al., 2011).
Functionally, changes in these speciﬁcmiRNAs inhibit Th2 cell dif-
ferentiation by inhibiting B lymphoma Mo-MLV insertion region
1 homolog (BMI1) and IL-4 expression, providing evidence that
miRNAs inﬂuence T cell polarization. A recent study has identi-
ﬁed miR-29b as an IFN-γ-inducible miRNA in CD4+ memory T
cells, which acts in a negative feedback loop to control Th1 cell
FIGURE 1 | MicroRNA (miRNA) dysregulation in CNS lesions and
immune cells of MS patients. miRNAs that are up- (red) and down-regulated
(blue) in CNS lesions, NAWM, or immune system of MS patients have been
assigned to speciﬁc cell types. Dysregulation is associated with astrocytes
and oligodendrocytes in the CNS and naïveT cells, memoryT cells, Th17 cells,
Treg cells, and B cells in the immune system. Note that while in most cases
miRNA dysregulation has been speciﬁcally detected in the mentioned cell
types, miRNAs that are here assigned to oligodendrocytes, were done so
exclusively on the basis of their relevance to normal oligodendrocyte
biology.
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bias by inhibiting T-bet and IFN-γ transcription. In MS patients,
the increase in miR-29b suggests a dysregulation of this feedback
loop and an important factor that can bias Th1 cell differentiation
(Smith et al., 2012).
Th17 cells are a subset of effector T cells that contribute
to inﬂammation and tissue damage in autoimmune diseases,
including MS. Th17 cell differentiation is controlled by several
cytokines and growth factors, yet role(s) for miRNAs have not
been identiﬁed. miR-326 is signiﬁcantly increased in peripheral
blood leukocytes of MS patients, and is prominently expressed
by CD4+/IL17a+ T cells compared to other T cell and non-
T cell populations (Du et al., 2009). miR-326 targets Ets-1, a
negative regulator of T cell differentiation, thereby promoting dif-
ferentiation (Moisan et al., 2007). In experimental autoimmune
encephalomyelitis (EAE), an animal model of neuroinﬂamma-
tion, by using miRNA mimics and inhibitors in vivo it was shown
that overexpression of miR-326 increased Th17 cell number and
disease severity, while decreasing miR-326 expression resulted in
relatively mild EAE accompanied by fewer Th17 cells (Du et al.,
2009). Also in the EAE model, miR-301a regulates Th17-mediated
immune responses by targeting the IL-6/23-STAT3 pathway. Stud-
ies performed in vivo have demonstrated that modulating levels of
miR-301a can signiﬁcantly alter EAE severity (Mycko et al., 2012).
miR-155, an inﬂammatory-promoting miRNA that targets sup-
pressor of cytokine signaling (SOCS), is elevated inCD4+ T cells in
EAE. Targeting miR-155 using antisense oligonucleotides, resulted
in decreased EAE severity when administered both prior to and
after the onset of clinical scores (Murugaiyan et al., 2011). Mice
lacking miR-155 (mir-155−/−) have reduced EAE disease severity
accompanied by less CNS inﬂammation and decreased Th1 and
Th17 responses (O’Connell et al., 2010).
In B lymphocytes isolated from untreated RRMS patients, the
levels of 49miRNAs are reported tobe signiﬁcantly decreased com-
pared with healthy volunteers; in contrast, no miRNAs increased
signiﬁcantly (Sievers et al., 2012). Down-regulated miRNAs in B
cells of MS patients include miR-25, miR-106b, miR-93, miR-19b,
and miR-181a, which are essential for B cell development (Liang
and Qin, 2009). Examination of Treg cells in MS (De Santis et al.,
2010) has identiﬁed differential expression of 23 miRNAs com-
pared with healthy controls. Of particular interest, miR-106b and
miR-25 were among the signiﬁcantly decreased miRNAs, both of
which modulate TGF-β signaling (Petrocca et al., 2008).
miRNA DYSREGULATION IN CNS LESIONS
Approximately 60% of miRNAs identiﬁed to date are expressed
in the CNS, many of which are highly enriched or speciﬁc to
the CNS. Fine-tuning by miRNAs is key for proper gene expres-
sion during CNS development and normal function in adulthood,
whereas abnormal miRNA expression is associated with multi-
ple CNS disorders. Speciﬁcally, miRNA regulation is essential for
neurogenesis, neurite outgrowth, oligodendrocyte differentiation,
and myelin maintenance (Vo et al., 2005; Krichevsky et al., 2006;
Shin et al., 2009; Dugas et al., 2010; Zhao et al., 2010). Disruption
of miRNA function has been implicated in the pathogenesis of
diseases such as amyotrophic lateral sclerosis, Alzheimer’s disease,
and MS (Junker et al., 2009; Williams et al., 2009; Noorbakhsh
et al., 2011).
To date, few studies have proﬁledmiRNAexpression inCNS tis-
sue from MS patients, animal models, and inﬂammatory lesions of
other autoimmune diseases. Analyses of CNS tissue that examined
the proﬁle of miRNA expression found in active lesions, inactive
lesions, and normal appearing white matter (NAWM), together
provide a signature of 50 miRNAs that are up-regulated and 30
miRNAs that are down-regulated in MS in comparison to healthy
subjects (Junker et al., 2009; Noorbakhsh et al., 2011). Interest-
ingly, there is little overlap between miRNAs that are dysregulated
in different MS lesions and NAWM, suggesting that MS patho-
physiology is heterogeneous at the level of miRNA control of gene
expression.
Modiﬁed miRNA proﬁles detected in MS brain tissue may
derive from alterations in neural cells or the immune cells that
have inﬁltrated into the CNS parenchyma. Efforts have therefore
been made to assign dysregulated miRNAs to speciﬁc cell types
(Figure 1). Laser capture micro-dissection of active lesions has
revealed that many up-regulated miRNAs are expressed by T cells,
B cells, macrophages, and astrocytes (Junker et al., 2009). Com-
parison of the miRNA signatures of active lesions with healthy
astrocytes, oligodendrocytes, and axons, reveals that the 10 most
up-regulated miRNAs in active lesions are induced in astrocytes
by IL-1β treatment (Lau et al., 2008; Junker et al., 2009; Let-
zen et al., 2010; Moser and Fritzler, 2010; Natera-Naranjo et al.,
2010; Tarassishin et al., 2011). Among these highly expressed
miRNAs, miR-155 is also dysregulated in NAWM and in the
brains of EAE animals (Noorbakhsh et al., 2011; Lescher et al.,
2012; Zhu et al., 2012). Interestingly, miR-155 expression is also
increased in inﬂammatory lesions of patients and animal models
of rheumatoid arthritis and lupus, suggesting thatmiR-155dysreg-
ulation may have a broad role in promoting inﬂammation (Zhu
et al., 2012).
Analysis of predicted targets of miR-155 combined with mRNA
proﬁling of MS lesions has suggested several proteins that may be
regulated by miR-155 in the CNS of MS patients. Among these
candidates, CD47, ARK1C1, and ARK1C2 have been experimen-
tally validated as miR-155 targets (Junker et al., 2009; Noorbakhsh
et al., 2011). CD47 is a ubiquitously expressed protein that inhibits
macrophage phagocytosis and functions as a “don’t eat me” mes-
sage; miR-155-mediated down-regulation of CD47 is thought
to release macrophages inhibition and thereby promote myelin
breakdown (Junker et al., 2009). ARK1C1 and ARK1C2 are dif-
ferent isoforms of an enzyme encoding a 3-α-hydroxysteroid
dehydrogenase activity that is essential to the synthesis of neu-
rosteroids in the brain. Neurosteroid synthesis is impaired in
MS, and the underlying mechanism is thought to at least par-
tially depend on miR-155 and its negative regulation of ARK1C
enzymes (Noorbakhsh et al., 2011). miR-155 down-regulates lev-
els of astrocyte-derived cytokines produced in vitro in response to
IL-1β/IFN-γ, suggesting a role for miR-155 promoting cytokine
production in the brain. Interestingly, this effect is mediated
by the down-regulation of SOCS1, a negative regulator of cyto-
kine production that is directly targeted by miR-155 (Tarassishin
et al., 2011).
miR-146a also exhibits elevated levels of expression in active
MS lesions, EAE, and other autoimmune diseases (Junker et al.,
2009; Lescher et al., 2012; Zhu et al., 2012). This NF-κβ-induced
www.frontiersin.org January 2013 | Volume 3 | Article 311 | 3
“fgene-03-00311” — 2013/1/20 — 20:11 — page 4 — #4
de Faria et al. miRNAs and multiple sclerosis
miRNA was initially shown to constitute an important nega-
tive feedback loop regulating the innate immune response in
monocytes by targeting of IRAK1 (Taganov et al., 2006). How-
ever, more recent data have suggested that miR-146a-mediated
down-regulation of IRAK1 is associated with the reinforcement of
IRAK2-induced activation of NF-κβ and a sustained inﬂammatory
response in human astroglial cells (Cui et al., 2010). Further sup-
port for a pro-inﬂammatory role of miR-146a in the brain is the
evidence that miR-146a down-regulates the expression of comple-
ment factor H, a negative regulator of brain inﬂammation (Lukiw
et al., 2008).
Among down-regulated miRNAs, miR-23b levels are decreased
in MS inactive lesions, in the spinal cords of EAE mice and in
inﬂammatory lesions associated with rheumatoid arthritis or sys-
temic lupus erythematosus (Junker et al., 2009; Zhu et al., 2012).
Findings derived from transgenic animal models indicate that
miR-23b overexpression delays the onset of EAE and alleviates
disease severity. Remarkably, miR-23b transgenic mice that have
been irradiated and transferred with bone marrow of wild-type
mice display the same phenotype, suggesting that during the nor-
mal course of EAE, miR-23b must be down-regulated speciﬁcally
in brain-resident cells. Interestingly, IL-17, a pro-inﬂammatory
cytokine, down-regulates miR-23b in astrocytes cultured in vitro.
Target prediction andmicroarray analysis followingmiR-23bover-
expression revealed a list of potential targets that includes many
pro-inﬂammatory genes. Among these, TAB2, TAB3, and IKK-α
were experimentally validated as miR-23b targets. Notably, these
genes are up-regulated during EAE and mediate IL-17-, TNF-α-,
and IL-1β-induced activation of NF-κβ. Together, these results
provide evidence that miR-23b is a negative regulator of autoim-
mune inﬂammation that is down-regulated in MS lesions (Zhu
et al., 2012).
miRNAsmiR-214 andmiR-23a are among the fewmiRNAs that
are dysregulated in both active and inactive lesions (Junker et al.,
2009). Additionally, miR-214 is up-regulated in lesions associated
with other autoimmune diseases, whereas miR-23a is elevated in
the spinal cord of mouse and non-human primate EAE (Lescher
et al., 2012; Zhu et al., 2012). Elevation of miR-214 and miR-23a
in MS lesions may reﬂect ongoing remyelination: miR-214 is up-
regulated in oligodendrocytes during differentiation and miR-23a
overexpression promotes oligodendrocyte differentiation by
targeting and down-regulating lamin B (Lau et al., 2008; Lin and
Fu, 2009).
In inactive MS lesions, miR-219 and miR-338-5p are the
most down-regulated miRNAs (Junker et al., 2009). Expression
of these miRNAs was detected in human oligodendrocytes iso-
lated from the adult brain (de Faria et al., 2012). Importantly,
regulation of the enzyme ELOVL7 by miR-219 is essential for
myelin maintenance and axonal integrity in the adult mouse
CNS (Shin et al., 2009). Lower levels of these miRNAs detected
in inactive MS lesions may simply be due to the oligodendro-
cyte cell death that has occurred at these sites. In contrast,
miR-219 and miR-338 are increased in NAWM of MS patients,
along with other miRNAs that are normally up-regulated dur-
ing oligodendrocyte differentiation. Moreover, ﬁve miRNAs that
are normally down-regulated during oligodendrocyte differen-
tiation are also down-regulated in the NAWM of individuals
with MS (Lau et al., 2008; Letzen et al., 2010; Noorbakhsh et al.,
2011). Such a proﬁle, together with both miR-219 and miR-
338-5p targeting inhibitors of oligodendrocyte differentiation
such as Sox6, Hes5, and Zfp238 (Dugas et al., 2010; Zhao et al.,
2010), suggest that oligodendrocyte precursors are differentiat-
ing in NAWM, presumably for the purpose of remyelination. In
addition, miR-338 may have a role in MS pathology, as it is
found in healthy axons and targets neurosteroid synthesis enzymes
ARK1C1 and ARK1C2 (Natera-Naranjo et al., 2010; Noorbakhsh
et al., 2011).
Comparisonof miRNAs signatures reveals that 50%of themiR-
NAs that are up-regulated in MS in humans are also up-regulated
during EAE. In addition, ﬁve of the six miRNAs most up-regulated
during EAE are also up-regulated in active MS lesions (Junker
et al., 2009; Noorbakhsh et al., 2011; Lescher et al., 2012; Zhu et al.,
2012). In contrast, miR-326, the third most up-regulated miRNA
in MS is only slightly increased during EAE, and miR-650, the top
most up-regulated miRNA in MS is human-speciﬁc (Junker et al.,
2009; Lescher et al., 2012). Even though this mechanism of up-
regulation is not conserved, these miRNAs appear to be relevant
to the inﬂammatory response. miR-650 is also up-regulated dur-
ing rheumatoid arthritis and miR-326 directly targets CD47, and
as such, may be involved in the inhibitory release of macrophages
(Junker et al., 2009; Zhu et al., 2012).
In summary, miRNA dysregulation in MS lesions appears to
be a signiﬁcant contributor to the molecular mechanism that
underlies inﬂammation in MS. This is best exempliﬁed by the
up-regulation of pro-inﬂammatory miRNAs such as miR-155
and the down-regulation of anti-inﬂammatory miR-23b; these
changes occur speciﬁcally, but not exclusively, in astrocytes. It is
also clear that alterations in the normal miRNA signature reﬂect
both demyelination and CNS attempts to remyelinate degenerat-
ing axons. This is perhaps best illustrated by the up-regulation
of miR-219-5p, miR-338, and miR-23a in the NAWM: miRNAs
that promote oligodendrocyte differentiation. Although yet to be
demonstrated, miRNA signatures characteristic of degenerating
axons and activated microglia may also indicate miRNA dysregu-
lation andmay identify novelmiRNAs that contribute functionally
to MS.
DISCUSSION AND PERSPECTIVES
Proﬁles of blood cells andCNS lesions of MSpatients have revealed
that miRNA expression is dysregulated in MS. Accumulating evi-
dence indicate that such dysregulation is a relevant aspect of
the disease pathology and that disruption of miRNA expression
underlies biochemical alterations that occur in MS. Whether this
abnormal miRNA expression contributes to the initiation of the
disease has yet to be determined. It is possible that dysregula-
tion of pro-inﬂammatory miRNAs such as miR-326 and miR-155
triggers early events that lead to inﬂammation. miRNAs miR-326
and miR-155 modulate T cell polarization and may contribute to
CD4+T cell-mediated autoimmunity (Du et al., 2009; O’Connell
et al., 2010). In addition, elevated levels of these miRNAs con-
tribute to inﬂammation in the brain by releasing CNS-invading
macrophages from inhibition (Junker et al., 2009). Further inves-
tigation is necessary to evaluate the role of these and othermiRNAs
in the initiation of MS.
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The involvement of miRNAs in the pathology of MS suggests
that modulators of miRNA expression or function may be used
as disease-modifying therapeutics. In fact, anti-miR-326 and anti-
miR-155 injections reduce the severity of EAE (Du et al., 2009;
Murugaiyan et al., 2011) and EAE mice that are genetically modi-
ﬁed to overexpress miR-23b also develop a milder form of disease
(Zhu et al., 2012). A miRNA therapy would have to overcome
potential side effects arising from the ability of miRNAs to reg-
ulate multiple targets in diverse cell types. Packaging into lipid
vesicles containing appropriate receptors could serve to specify
miRNA delivery to the appropriate cell type and reduce off-target
effects. Interestingly, endogenous miRNAs are transported in the
blood, inside plasma membrane-derived vesicles, and exogenous
miRNAs can be successfully delivered usingHDLparticles puriﬁed
from the blood (Valadi et al., 2007; Vickers et al., 2011).
Investigating the functional consequences of altered miRNA
expression in CNS lesions and immune cells of MS patients poses
a large challenge given the multiple mRNAs targeted by any one
miRNA. Combinations of miRNA and mRNA/protein signatures
may represent a possible approach to overcome this difﬁculty.
Given the intimate association of axons, myelin, and astrocytes,
in addition to the cross-talk between the adaptive and innate
immune systems, it is critical to understand how manipulating
speciﬁc miRNAs affects the biology of individual cell types, and
also how altering miRNAs impacts the overall CNS and immunity.
Further investigating the consequences of miRNA dysregulation
will contribute to a better understanding of the pathophysiology
of MS.
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